2024-03-13 13:24:05 ET
ADC Therapeutics SA (ADCT)
Q4 2023 Results Earnings Conference Call
March 13, 2024, 08:30 AM ET
Company Participants
Nicole Preiss-Riley - Executive Director, Head of Communications
Ameet Mallik - Chief Executive Officer
Kristen Herrington-Smith - Chief Commercial Officer
Mohamed Zaki - Chief Medical Officer
Patrick van Berkel - Chief Scientific Officer
Jose Carmona - Chief Financial Officer
Conference Call Participants
Naureen Quibria - Capital One Securities, Inc.
Brian Cheng - J.P. Morgan
Gregory Renza - RBC Capital Markets
Kelly Shi - Jefferies
Presentation
Operator
Welcome to the ADC Therapeutics Fourth Quarter and Full-Year 2023 Financial Results Conference Call. My name is Norma and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. [Operator Instructions].
I will now turn the call over to Nicole Riley, Head of Communications. Nicole, you may now begin.
Nicole Preiss-Riley
Thank you, operator. This morning, we issued a press release announcing our fourth quarter and full year 2023 financial results and business updates. This release is available on the ADCT website at ir.adctherapeutics.com under the Press Releases section.
On today's call, Ameet Mallik, Chief Executive Officer; Kristen Herrington-Smith, Chief Commercial Officer; Mohamed Zaki, Chief Medical Officer; Patrick van Berkel, Chief Scientific Officer; and Pepe Carmona, Chief Financial Officer, will discuss recent business highlights and review our fourth quarter and full-year 2023 financial results before opening the call for questions.
Before we begin, I would like to remind listeners that some of the statements made during this conference call will contain forward-looking statements within the meaning of the Safe Harbor provisions of the US Private Securities Litigation Reform Act of 1995.
These forward-looking statements are subject to certain known and unknown risks and uncertainties, and actual results, performance and achievements could differ materially. They are identified and described in today's press release and the accompanying slide presentation on slide 2 and in the company's filings with the SEC, including Form 10-K, 10-Q and 8-K....
Read the full article on Seeking Alpha
For further details see:
ADC Therapeutics SA (ADCT) Q4 2023 Earnings Call Transcript